Please login to the form below

Not currently logged in

Sepracor's epilepsy drug cuts seizures

Sepracor has said its esclicarbazepine acetate drug causes a significant reduction in the frequency of seizures
Sepracor has said that results of its randomised, double-blind trials involving 1,049 patients show that compared to a placebo, patients given its esclicarbazepine acetate drug (in either 800mg or 1200mg doses) experience a significant reduction in the frequency of seizures.

The phase III trials involved patients, who despite being treated with epilepsy drugs, experienced four or more partial seizures per month. Over a 12-week period, patients receiving the 800mg dosage showed a 35.4 per cent relative reduction in seizure frequency. Patients receiving the 1200mg dose showed a 38.8 per cent reduction.

In an open-label follow up study lasting 52 weeks, patients who were given esclicarbazepine acetate showed statistically significant improvements in quality of life.

Esclicarbazepine acetate is designed to be used in combination with other anti-epileptic drugs. It is a sodium channel blocker that works by blocking electrical signals in the brain to reduce the frequency of partial-onset seizures.

19th June 2008


Featured jobs

Subscribe to our email news alerts


Add my company

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...